Specialized Medical Devices

INSPIRA TECH OXY BHN LTD C/WTS 16/07/2026 (TO PUR COM)

OPTIMI HEALTH CORP

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

MetaVia

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Pinned News

置顶新闻

NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation

Ticker Change

代码变更

From Today 2026.05.20 (EST) changed to QTEXW

IINN

IINNW

Inspira Technologies Oxy B.. Ltd. announced a $580,000 purchase order from NYU Langone Hospital for its FDA-cleared ART100 systems, following a successful clinical evaluation. The order, facilitated through Inspira's U.S. distributor, is set for immediate delivery and supports the company's strategic initiatives. Inspira is listed on Nasdaq under IINN and IINNW.

Unusual Whales

Inspira Tech OXY

SPDR S&P Health Equip

iShares US Medical Devices

Ra'anana, Israel, 11th May 2026 - Today, Inspira™ Technologies OXY B.. Ltd. on the NASDAQ under tickers IINN and IINNW, based in Israel, shared a communication with its shareholders from CEO Dagi Ben-Noon.

Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan

Inspira™ Technologies OXY B.. Ltd., based in Ra'anana, Israel, revealed that they have received a Notification Letter from Nasdaq on February 9, 2026. The letter stated that the company, listed under NASDAQ as IINN and IINNW, is not meeting the minimum bid price requirement outlined in Nasdaq Listing Rule 5550(a)(2). This is due to the closing bid price of the company's Ordinary Shares falling below $1.00 per share for the past 30 consecutive business days.

Inspira Technologies receives Nasdaq notification for not meeting minimum bid price, shares below $1.00 for 30 days.

INSPIRA TECH OXY BHN LTD C/WTS 16/07/2026 (TO PUR COM)(IINNW.US)

NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation

Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan

Inspira Technologies receives Nasdaq notification for not meeting minimum bid price, shares below $1.00 for 30 days.